SCHEMBL1895337

SCHEMBL1895337

O=C(O)c1cc2ccncc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.58
KDM4E B2RXH2 2/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 2/20 0.58
MAPT P10636 1/20 0.58
SRD5A2 P31213 1/20 0.58
HRH4 Q9H3N8 2/20 0.57
SMAD3 P84022 1/20 0.50
EIF4A3 P38919 1/20 0.49
F7 P08709 1/20 0.49
F3 P13726 1/20 0.49
PIN1 Q13526 1/20 0.49
PDPK1 O15530 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
APEX1 P27695 1/20 0.49
CYP2C19 P33261 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29414290 1.00 DAO (0.58) DAOKDM4EHPGDHSD17B10MAPT
Hydrochloric Acid SCHEMBL29228902 0.98 DAO (0.56) DAOKDM4EHPGDHSD17B10MAPT
SCHEMBL168527 0.86 DAO (0.58) DAOKDM4EHPGDHSD17B10MAPT
SCHEMBL1884988 0.84 HRH4 (0.56) DAOKDM4EHRH4MAP2K1IDO1
SCHEMBL4273622 0.84 HRH4 (0.59) DAOMAPTHRH4MAP2K1IDO1
SCHEMBL30903100 0.84 HRH4 (0.59) DAOMAPTHRH4MAP2K1IDO1
SCHEMBL23212302 0.83 HRH4 (0.55) DAOKDM4EHRH4MAP2K1IDO1
SCHEMBL4272549 0.82 MAP2K1 (0.68) DAOKDM4EHPGDHSD17B10MAPT
SCHEMBL4279557 0.81 MAP2K1 (0.58) DAOHRH4TSHRMAP2K1IDO1
SCHEMBL28426144 0.81 HRH4 (0.57) DAOMAPTHRH4MAP2K1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013097052-A1 BROMODOMAIN INHIBITORS ABBOTT LABORATORIES (US) 2013-07-04 WO claimed
CN-102675312-A Synthesis method of ethyl 1H-pyrrolo[2,3-C]pyridyl-2-carboxylate CGENE TECH SUZHOU CHINA CO LTD 2012-09-19 CN claimed
EP-1768979-B1 OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF MERCK SERONO SA (CH) 2010-09-29 EP claimed
EP-1768979-A1 OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2007-04-04 EP claimed
WO-2006008303-A1 OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-01-26 WO claimed
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-01-22 US disclosed
EP-4370207-B1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-12-17 EP disclosed
US-12473302-B2 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-11-18 US disclosed
WO-2025085852-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS, INC. (US) 2025-04-24 WO disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP disclosed
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2024-11-07 US disclosed
US-20240287092-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-08-29 US disclosed
WO-2003022856-A1 SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES PHARMACIA & UPJOHN COMPANY (US) 2003-03-20 WO disclosed
US-6380230-B1 FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS SANOFI-SYNTHELABO (FR) 2002-04-30 US disclosed
CN-1276790-A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them SANOFI SA (FR) 2000-12-13 CN disclosed
CN-1025676-C Non-peptidic renin inhibitors PFIZER (US) 1994-08-17 CN disclosed
EP-0321192-B1 Non-peptidic renin inhibitors PFIZER (US) 1993-10-27 EP disclosed
US-4923864-A RENIN INHIBITORS PFIZER INC. (US) 1990-05-08 US disclosed
CN-1034366-A The blood vessel tension peptide protoenzyme inhibitor of non-peptide PFIZER (US) 1989-08-02 CN disclosed
EP-0321192-A2 Non-peptidic renin inhibitors PFIZER INC. (US) 1989-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287092-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE HTR3C, HRH4, DRD3 DAO 3228/4885KDM4E 1319/4885HPGD 2848/4885
US-12473302-B2 4-phenylpiperidines, their preparation and use HTR3C, HRH4, DRD3 DAO 3228/4885KDM4E 1319/4885HPGD 2848/4885
US-20240368137-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 DAO 4065/4885KDM4E 1723/4885HPGD 1466/4885
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE CLN6, NR2E3, CBR3 DAO 2773/4885KDM4E 3025/4885HPGD 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.